NEW YORK, Jan. 13, 2017 -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Fenix Parts, Inc. (“Fenix Parts” or the “Company”) (NASDAQ:FENX) in the United States District Court for the District of New Jersey on behalf of purchasers of common stock of Fenix Parts between May 14, 2015 and October 12, 2016 (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the Securities Exchange Act of 1934.
According to the Complaint, Defendants made false and/or misleading statements and/or failed to disclose that its inventory valuation methods were inadequate; that its tools to calculate goodwill impairment were inadequate; that it was participating and/or had participated in activity that would lead to an SEC investigation; and that as a result, Fenix’s statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When this information was released to the public, the value of Fenix stock fell severely, causing investors harm.
If you wish to serve as lead plaintiff, you must move the Court no later than March 13, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, or to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].
Please visit our website at http://www.gme-law.com for more information about the firm.


Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Apple Turns 50: From Garage Startup to AI Crossroads
First Western Ship Transits Strait of Hormuz Since Iran War Began
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 



